Deucravacitinib, an Oral Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-controlled Trial (PSORIATYK SCALP). J of Skin [Internet]. 2024 Nov. 18 [cited 2025 Apr. 3];8(6):s420. Available from: https://skin.dermsquared.com/skin/article/view/3088